NIT
ITCI

NumerixS Investment Technologies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

NumerixS Investment Technologies’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,775
Closed -$97K – 890
2020
Q2 		$97K Buy
+3,775
New +$76.4K 0.03% 597
2019
Q4 		– Sell
-10,800
Closed -$81K – 1275
2019
Q3 		$81K Buy
+10,800
New +$104K 0.02% 614
2018
Q4 		– Sell
-9,000
Closed -$203K – 1437
2018
Q3 		$203K Sell
9,000
-400
-4% -$8.36K 0.04% 579
2018
Q2 		$167K Buy
+9,400
New +$191K 0.04% 579
2018
Q1 		– Sell
-1,100
Closed -$16K – 1316
2017
Q4 		$16K Buy
+1,100
New +$17K ﹤0.01% 1025
2017
Q2 		– Sell
-11,830
Closed -$192K – 1388
2017
Q1 		$192K Buy
11,830
+3,230
+38% +$46.7K 0.02% 731
2016
Q4 		$130K Buy
+8,600
New +$121K 0.02% 802

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NumerixS Investment Technologies's ITCI Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 3,775 shares — an estimated $97K sold.

NumerixS Investment Technologies first reported a position in ITCI in Q4 2016 and held it in 7 quarters. The position peaked at $203K in Q3 2018. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 3,775 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $97K.
  • NumerixS Investment Technologies first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 7 quarters.
  • NumerixS Investment Technologies's Intra-Cellular Therapies Inc. position peaked at $203K in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.